VZVasiliy Zaplutanov

Vasiliy Zaplutanov

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Vasiliy Zaplutanov has a total of 43 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • The Effectiveness of Various Antibacterial Therapy Regimens for Helicobacter pylori Eradication in Patients in the Northwestern Federal District, and Factors Influencing It

    by A. V. Tryapitsyn, K. A. Alekseeva, A. A. Krasnov, V. A. Zaplutanov

    The relevance of the study is determined by the high prevalence of Helicobacter pylori infection in Russia (50-80% of the population) and the growing problem of antibiotic resistance, which requires constant monitoring of the effectiveness of various eradication therapy regimens. The aim of the study was to evaluate the effectiveness of various antibacterial therapy regimens for H. pylori eradication in patients of the North-Western Federal District, as well as to identify factors influencing the success of the treatment. Material and methods . A retrospective analysis of 201 medical histories of patients with H. pylori-associated diseases was conducted. The following methods were used: video gastroduodenoscopy, rapid urease test, histological biopsy specimens, and 13 C-urea breath test. Statistical processing was performed using the R software environment. The study results showed an 86.6% overall eradication therapy effectiveness. The best results were demonstrated by regimens containing levofloxacin (96.7%), with the combination of levofloxacin and furazolidone showing 100% effectiveness. A positive impact was observed with double-dose esomeprazole (95.1% effectiveness) and alpha-glutamyl-tryptophan (95.2% effectiveness). Probiotic use did not show statistically significant influence on the outcome. A decrease in the effectiveness of the classical regimen with amoxicillin and clarithromycin to 85.2% was revealed, which may be associated with widespread antibiotic therapy during COVID-19. The practical significance of this study lies in determining the most effective eradication therapy regimens for the region, as well as identifying factors that enhance treatment success. The results can be used to optimize approaches to H. pylori infection therapy.

  • Study of the Antiviral Mechanism of Cytovir®-3 Against Respiratory Viruses In Vitro

    by V. V. Zarubaev, V. S. Smirnov, T. A. Kudryavtseva, S. V. Petlenko, P. A. Ilina, V. A. Zaplutanov

    Background. Modern clinical practice often excludes the possibility of differential diagnostics for acute respiratory viral infection pathogens and identification of a specific viral pathogen. In this regard, it is important to search for drugs with a broad spectrum of activity against pathogens of acute respiratory viral infections. The aim of the study was to assess the antiviral activity of the drug Cytovir®-3 in vitro against the cytopathogenic effect of human adenovirus. Material and methods. The antiviral effect of the drug Cytovir®-3 in comparison with the drug Umifenovir against human adenovirus type 5 was studied on Vero cell culture. The drugs were administered 1 hour before (prophylactic regimen) and 1 hour after (therapeutic regimen) infection of the cell culture with the virus. The working concentration range for the studied drugs was determined based on the 50% cytotoxic concentration values, calculated based on the results of the microtetrazolium (MTT) assay. Results and discussion . The drug Cytovir®-3 in two application regimens (therapeutic or prophylactic) demonstrated antiviral efficacy in vitro against human adenovirus in the non-toxic range (0-631 µg/ml) regardless of the application scheme (therapeutic or prophylactic ). Conclusion . The in vitro antiviral activity of the drug Cytovir®-3 against human adenovirus has been proven. Moreover, in all series of experiments, Cytovir®-3 had a selectivity index comparable to that of the reference drug Umifenovir.

  • Dynamics of structural changes in the gastric mucosa and their clinical manifestations during the natural course of chronic autoimmune atrophic gastritis and in response to treatment with alpha-glutamyl-tryptophan. Clinical case

    by A.V. Tryapitsyn, V.A. Zaplutanov

    Chronic autoimmune atrophic gastritis is one of the key risk factors for the development of gastric malignancies. Objective: To describe a clinical case illustrating the dynamics of long-term structural changes in the gastric mucosa in the absence of treatment and following therapy with alpha-glutamyl-tryptophan. Clinical case. A chronological account is presented detailing the diagnosis, treatment, clinical features, and histological findings from gastric mucosal biopsies in a 57-year-old patient, monitored from 2020 to 2025. Conclusion. This clinical case demonstrates the potential of alpha-glutamyl-tryptophan as a course-based therapy for the early and timely management of structural changes in the gastric mucosa associated with chronic autoimmune atrophic gastritis.


  • Systemic review and meta-analysis of the three-component drug regimen (alpha-glutamyl-tryptophan, bendazole, ascorbic acid) prophylactic efficacy

    by V.S. Smirnov, S.V. Petlenko, A.A. Krasnov, V.A. Apryatina, V.A. Zaplutanov, Ya.YU. Skripacheva

    Influenza and acute respiratory viral infections (ARVI) have a high prevalence, which determines their clinical and economic relevance. Agents activating nonspecific antiviral immunity mechanisms can be used to prevent these infections. Objective. To perform a systematic review and meta-analysis of the results of clinical studies on the preventive antiviral effectiveness of the three-drug regimen (alpha-glutamyl-tryptophan, bendazole, and ascorbic acid) against influenza and acute respiratory viral infections. Materials and methods. Following the PRISMA guidelines, the results of controlled clinical studies on the preventive effectiveness of the three-drug regimen (alpha-glutamyl-tryptophan, bendazole, and ascorbic acid) were selected using the recommended databases. The effectiveness was evaluated based on serum levels of total and stimulated interferon, serum and salivary immunoglobulin A levels, and oxidative and phagocytic activity of granulocytes and monocytes. The risk of bias and the quality of studies were assessed using the RoB 2 tool. The meta-analysis was conducted using the Meta package of the R statistical software and included an assessment of the generalized differences in the mean values of the parameters before and after the treatment course (Z-test), an assessment of the fixed/random weight of the studies, and verification of their heterogeneity (I2 test). Results. The results of four clinical studies, published between 2018 and 2021, were selected. A statistically significant (generalized) treatment effect size was identified for induced oxidative activity of granulocytes (an increase of 2.18 standard deviations; p=0.0004; I2=87.2%); salivary IgA levels (an increase of 0.73 standard deviations; p=0.0001; I2=86.6%); phagocytic activity of monocytes (an increase of 1.39 standard deviations; p=0.0001; I2=90.9%); phagocytic activity of granulocytes (an increase of 0.85 standard deviations; p=0.0031; I2=82.7%). Conclusion. The studied treatment regimen demonstrated an adaptive-activating effect on various elements of innate antigen-nonspecific immunity, contributing to the prevention of influenza and acute respiratory viral infections.


  • Open Access

    Virucidal Activity of the Drug «Thymogen®», a Nasal Dosed Spray, Against Human Respiratory Viruses In Vitro

    by V. S. Smirnov, V. V. Zarubaev, T. A. Kudryavtseva, I. L. Esaulkova, A. S. Volobueva, V. A. Zaplutanov, S. V. Petlenko

    Background. Respiratory syncytial virus (RSV) and parainfluenza virus together account for up to 40% of the pathogens causing acute respiratory infections in children and adults. RSV infection does not result in the development of stable immunity, which necessitates the search for effective methods of its drug-based prevention. The aim of the work was to study of the virucidal activity of the drug Thymogen®, a dosed nasal spray, against human respiratory viruses (parainfluenza virus and respiratory syncytial virus) in vitro. Material and methods. The virucidal effect of the drug Thymogen®, a dosed nasal spray, was studied in vitro on the Vero (ATCC CCL-81) cell culture in comparison with the drugs Hexoral® and Lizobact COMPLETE® against the parainfluenza virus and respiratory syncytial virus. The work was carried out in two stages: a study of the cytotoxicity of Thymogen® followed by a study of the virucidal effect at working range of drug concentrations of the drug. Results and discussion. The cytotoxicity assessment of the drug Thymogen®, a dosed nasal spray, allowed the use of a working range of drug concentrations of 0–63%. The virucidal activity of the drug Thymogen®, a dosed nasal spray, was revealed against the respiratory syncytial virus in vitro, starting with a drug concentration of 1.2%; and the parainfluenza virus, starting with a drug concentration of 0.4%. Conclusion. The obtained data may serve as a basis for conducting appropriate clinical studies on the use of the drug Thymogen®, a dosed nasal spray, in patients with acute respiratory viral infections, including respiratory syncytial virus and/or human parainfluenza virus as infectious agents.

  • Open Access

    Study of the Protective Activity of Thymogen® Dosed Nasal Spray on a Model of Experimental Influenza Pneumonia in Laboratory Animals

    by V. V. Zarubaev, A. V. Garshinina, Ya. L. Esaulkova, М. Г. Михальский, V. S. Smirnov, T. A. Kudryavtseva, S. V. Petlenko, V. A. Zaplutanov

    Introduction. Due to the ability of the influenza virus to mutate, it is necessary to constantly search for new drugs with preventive and direct antiviral effects.The aim of the study is to investigate the protective antiviral properties of the drug Thymogen®, a dosed nasal spray, on a model of lethal influenza pneumonia in laboratory animals.Material and methods. White mature mice were selected for the experiment on the antiviral activity of the tested drug samples against H1N1 influenza virus; the mice were divided into the following groups (30 animals each): two negative control groups; two groups receiving Thymogen®, a dosed nasal spray (before and after infection); one group of animals received Tamiflu®, and one received Hexoral®. The mortality of animals with influenza pneumonia was assessed; histological and morphometric analyses were also carried out.Results and discussion. The morphological picture of the lungs of animals correlated with their protective activity when analyzing the survival of animals. The normalization of tissue structure was pronounced the most in the group of animals infected with the virus, pre-incubated with Thymogen®, a dosed nasal spray, and in the group receiving Tamiflu®. Moreover, the viral load in the lungs was lower by 1.5 and 1.2 orders of magnitude in the group receiving Thymogen®, dosed nasal spray, compared to the negative control group (the 3rd and the 6th days of the experiment, respectively), which corresponds to a decrease in the intensity of viral reproduction by 31.6 and 15.8 times

  • Open Access

    Influence of alpha-glutamil-tryptophan on the background and induced activity of factors of adaptive immunity for prevention

    by A. A. Ruleva, A. A. Krasnov, S. V. Petlenko, V. A. Zaplutanov, V. A. Apryatina

    Background. During the ongoing COVID-19 pandemic and in the season of rising incidence of other respiratory infections, it is relevant to use preventive measures of non-specific prophylaxis. Synthetic peptides are widely considered as a tool. The representative of this group is the synthetic analogue of thymus regulatory peptides Thymogen, which has been used in Russia for more than 20 years in the treatment of acute and chronic infection diseases.The aim of the study. To evaluate the effect of Thymogen, a dosed nasal spray, on induced parameters of the immune system during prophylactic use in healthy volunteers.Materials and methods. Twenty healthy volunteers received Thymogen nasal dosed spray (JSC “Cytomed”, Russia) at a dose of 25 μg twice a day for 10 days. A comparative assessment of immunological parameters was carried out in dynamics: before the start of therapy, on days 6 and 11 of taking the drug and 14 days after the end of the course. Clinical observation was carried out from day 1 to day 11, registration of adverse events – the entire period of the study for 24 days. The first day was considered the day the drug was started.Results. In the course of the work, according to the data of immunological examination, a statistically significant increase in the virus-induced production of interferon alpha (INF-α) by a culture of peripheral blood cells was revealed. The growth rate was recorded on day 11 of taking Thymogen and persisted for 14 days after the end of the course. Significant differences in the dynamics of bactericidal and phagocytic activity of neutrophils, serum α- and γ-interferon were not obtained.Conclusion. The use of Thymogen spray at a dose of 25 μg for 10 days was safe and contributed to a significant induction of interferon-alpha in response to exposure to a viral pathogen, which allows us to recommend the drug for prophylactic use during the period of rising incidence of acute respiratory diseases.

  • Study of the Mechanism of Antiviral Activity of Cytovir®-3 Against Respiratory Viruses In Vitro

    by V. V. Zarubaev, V. S. Smirnov, T. A. Kudryavtseva, S. V. Petlenko, A. V. Slita, Хоанг Мин, V. A. Zaplutanov

    Introduction. The requirements of modern clinical guidelines for the treatment of respiratory viral infections suggest the possibility of identifying a specific viral pathogen. In this regard, the search for drugs with selective activity against respiratory syncytial virus and parainfluenza virus is relevant. The purpose of the work is to study the antiviral activity of the drug Cytovir®-3 in vitro in relation to the cytopathogenic effect of respiratory viruses (parainfluenza virus and respiratory syncytial virus). Material and methods. The antiviral effect of Cytovir®-3 in comparison with Umifenovir against parainfluenza virus and respiratory syncytial virus was studied on Vero cell culture. Drugs were administered 1 hour before (prophylactic regimen) and 1 hour after (treatment regimen) infection of the cell culture with respiratory viruses. The working range of concentrations of the studied drugs was calculated based on the values of 50% cytotoxic concentration calculated based on the results of a quantitative microtetrazole test. Results and discussion. The drug Cytovir®-3 in two schemes of application (therapeutic or prophylactic) showed its antiviral efficacy in vitro against respiratory syncytial virus and parainfluenza virus due in the non-toxic range (0–794 µg/ml). At the same time, the suppressive effect of the drug Cytovir®-3 against the parainfluenza virus begins at lower concentrations of the drug with its early (preventive) introduction into cell culture (250 mcg/ml). Conclusion. Antiviral activity of Cytovir®-3 has been proven in vitro against parainfluenza virus and respiratory syncytial virus. At the same time, in all series of experiments, Cytovir®-3 had a higher index of selectivity of antiviral action than that of the comparison drug Umifenovir.


  • Open Access

    Endoscopic and morphometric analysis of the reduction of acute inflammatory process in the gastric mucosa after therapy with Regasthym Gastro

    by N V Baryshnikova, Y P Uspenskiy, Y A Fominykh, S V Petlenko, V A Zaplutanov, V A Apryatina, A A Krasnov

    Aim. To analyze the anti-inflammatory efficacy of Regasthym Gastro (alpha-glutamyl-tryptophan) in the treatment of patients with chronic atrophic gastritis according to endoscopic and morphometric studies. Materials and methods. As part of a double-blind placebo-controlled study, the results of gastroscopy and histological (morphometric) studies were retrospective analyzed in 80 patients diagnosed with chronic atrophic gastritis associated with Helicobacter pylori in exacerbation: 43 patients took Regasthym Gastro, 37 patients placebo. The conclusions of the gastroscopy were structured in the form of a standardized scale, which included an assessment of criteria in points (from 0 to 3): thickness of folds, hyperemia, edema of the gastric mucosa, the signs of atrophy, metaplasia; the severity of the erosive process. The sum of points according to all criteria was used to assess the dynamics of the inflammatory process: positive dynamics; lack of dynamics; the pathological process is progressing. The results of the endoscopic examination were compared with morphometry data (the number of inflammation pool cells per 1 mm2 of gastric mucosa). Statistical processing of the results was carried out using the Statistica 12 application software package. Results. According to the gastroscopy, before therapy, hyperemia of the gastric mucosa was present in 82.5%, edema in 53.8%, erosion in 17.5%, signs of metaplasia in 12.5% of patients. After therapy with the investigated drug a statistically significant decrease in the severity of edema of the gastric mucosa (p=0.008), the total set of signs of acute inflammatory process (p=0.006), a decrease in the proportion of outcomes with negative dynamics of the inflammatory process (p=0.038) was revealed. Statistically significant (p0.05) correlations were found between gastroscopy data of inflammation and the number of neutrophil, eosinophil granulocytes, macrophages and lymphocytes per 1 mm2. Conclusion. Regasthym Gastro contributes to a significant decrease in the severity of the inflammatory process according to the evaluation of the results of gastroscopy and morphometry. It is possible to recommend the inclusion of this drug in the complex therapy of chronic gastritis to increase the effectiveness and reduce the risks of progression of inflammation.


  • Possibilities of suppressing the cytopathogenic effect of SARS-CoV-2 coronavirus according to the results of the antiviral activity of Cytovir®-3 in vitro study

    by V. S. Smirnov, I. A. Leneva, T. A. Kudryavtseva, E. B. Fayzuloev, V. A. Zaplutanov, S. V. Petlenko, N. P. Kartashova, A. V. Gracheva, E. R. Korchevaya

    Introduction. The COVID-19 pandemic has stimulated the search for drugs with specific antiviral activity against the new pathogenic strain of the SARS-CoV-2 coronavirus. First of all, scientific search was aimed at studying drugs with already proven efficacy against influenza and ARVI.The aim of this workwas to study the antiviral activity of Cytovir®-3in vitroin relation to the cytopathogenic effect of the SARS-CoV-2 virus.Material and methods.The antiviral activity of the drug Cytovir®-3 against the SARS-CoV-2 virus was studied in experimental modelsin vitroon Vero CCL81 cell culture (ATCC). The maximum tolerated concentration and the 50% cytotoxic dose were determined using a quantitative microculture tetrazolium test assay to calculate the working range of the concentrations of the test drug.Results and discussion.As a result of the study, it was shown that the greatest activity of the drug was manifested when it was added to the cells 24 hours before and 1 hour and 24 hours after viral infection, the inhibition level reached 53% (>IC50) at the drug concentrations of 105, 55, and 85 µg/ml, respectively. Cytovir®-3 suppressed the viral activity of SARS-CoV-2 in the dose range from 10 µg/ml to 105 µg/ml under the indicated infection conditions. It was found that the drug did not exhibit cytotoxic effects on the Vero cell culture in the range of antiviral doses.Conclusion.The antiviral activity of Cytovir®-3 against the SARS-CoV-2 virus has been proven due to the achievement of IC50, which is below the maximum tolerated dose of 149 µg/ml.